Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC

Research output: Contribution to journal › Article › peer-review

Original language	German (Austria)
Number of pages	2
Journal	Journal of Thoracic Oncology
DOIs	https://doi.org/10.1016/j.jtho.2022.07.680
Publication status	Published - Sept 2022

Fields of science

@article{e7198a7b2fa64bf486f9453594b78e4d,

title = "Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC",

author = "Vanessa Rambousek and David Lang and Andreas Horner and Bernhard Kaiser and Bernd Lamprecht",

year = "2022",

month = sep,

doi = "10.1016/j.jtho.2022.07.680",

language = "Deutsch ({\"O}sterreich)",

journal = "Journal of Thoracic Oncology",

issn = "1556-1380",

}

TY - JOUR

T1 - Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC

AU - Rambousek, Vanessa

AU - Lang, David

AU - Horner, Andreas

AU - Kaiser, Bernhard

AU - Lamprecht, Bernd

PY - 2022/9

Y1 - 2022/9

U2 - 10.1016/j.jtho.2022.07.680

DO - 10.1016/j.jtho.2022.07.680

M3 - Artikel

SN - 1556-1380

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

ER -